drugset / Trial / NCT03666351

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

NCT03666351

Phase 4 Completed 128 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupSingle-blindTreatment

Summary

To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on improvement of left ventricular hypertrophy and its safety

Timeline

Start
2018-10-18
Primary completion
2022-07-25
Completion
2022-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Chlorthalidone Other / unclassified 12.5 mg
Subject Losartan Other / unclassified 50 mg
Subject Losartan Other / unclassified 100 mg